Hormones and Cardiovascular Disease
Director: Pierre-Yves Scarabin

 

Hormones and Cardiovascular Disease
Director: Pierre-Yves Scarabin

 

Hormones and Cardiovascular Disease
Director: Pierre-Yves Scarabin

 

Venous thromboembolism, including pulmonary embolism and deep vein thrombosis, is one of the major harmful effects of hormone therapy among postmenopausal women. The Million Women Study (MWS), a large cohort study set up in United Kingdom, provided further evidence that oral but not transdermal estrogen would increase the risk of venous thromboembolism. This study included over 1 000 000 postmenopausal women aged 50-64 years. During an average follow-up time of about 3 years, 2 200 cases of venous thromboembolism were identified. The risk of thrombosis was greater for current users of oral estrogens compared with non users. By contrast, there was no significant change in this risk among women using transdermal estrogens.

Marianne Canonico contributed to the MWS data analysis during her postdoctoral position. The results published in the Journal of Thrombosis and Haemostasis, together with early findings of the ESTHER study and other recent data, provide strong epidemiological evidence for promoting transdermal estrogens in postmenopausal women requiring hormone therapy, especially in obese women who are at high risk for thrombosis.

© Esther 2019